Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment

AIMS: Renal disease is a frequent comorbidity of type 2 diabetes mellitus (T2DM) and an important factor complicating the choice of glucose-lowering drugs. The aim of this analysis was to evaluate the efficacy and safety of the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin (5 mg/day) in mono, d...

Descripción completa

Detalles Bibliográficos
Autores principales: Groop, P-H, Del Prato, S, Taskinen, M-R, Owens, D R, Gong, Y, Crowe, S, Patel, S, von Eynatten, M, Woerle, H-J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288982/
https://www.ncbi.nlm.nih.gov/pubmed/24612167
http://dx.doi.org/10.1111/dom.12281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288982/
https://www.ncbi.nlm.nih.gov/pubmed/24612167
http://dx.doi.org/10.1111/dom.12281

Ejemplares similares